In the NewsMedCity News: This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source In the News / lsc-webmaster
In the NewsCrain’s Chicago Business: Venture capital, Big Pharma put $105M into Cour Pharmaceuticals’ immunology therapies In the News / lsc-webmaster
In the NewsBioSpace: Cour Raises $105M in Series A Round with Backing From Big Pharma In the News / lsc-webmaster
In the NewsChicago Inno: Cour Pharmaceuticals lands $105 million for next phase of clinical trials In the News / lsc-webmaster
In the NewsEndpoints News: Chicago-area autoimmune biotech gets pharma backing in $105M round for two PhII trials In the News / lsc-webmaster
In the NewsSTAT News: Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million In the News / lsc-webmaster
In the NewsGenetic Engineering & Biotechnology News (GEN): Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity In the News / lsc-webmaster
In the NewsBioPharma Dive: Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease In the News / lsc-webmaster
In the NewsBioWorld: Cour’s nanoparticles shut off autoimmunity with $105M series A In the News / lsc-webmaster
In the NewsChemical Engineerings & News (C&EN): Roche, Pfizer, Bristol Myers back immune disease firm Cour Pharmaceuticals In the News / lsc-webmaster
